We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01259063
First Posted: December 13, 2010
Last Update Posted: June 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Novartis Pharmaceuticals
New York University
University of Hawaii
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2017
  Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)